8:30 AM ET
8-K
Business Update
Coya Therapeutics Business Update
Coya Therapeutics announced plans to initiate an open-label extension for its Phase 2/3 ALSTARS trial of COYA 302 in ALS to collect long-term safety and efficacy data. Due to resource prioritization for the ALS program, the company has delayed the planned initiation of its Phase 2 trial for COYA 302 in frontotemporal dementia from late 2026 to 2027.